JUNIOR STRENGTH MOTRIN Drug Patent Profile

When do Junior Strength Motrin patents expire, and what generic alternatives are available?

Junior Strength Motrin is a drug marketed by Kenvue Brands and is included in two NDAs.

The generic ingredient in JUNIOR STRENGTH MOTRIN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-six suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Junior Strength Motrin

A generic version of JUNIOR STRENGTH MOTRIN was approved as ibuprofen by STRIDES PHARMA INTL on September 24^th, 1986.

Summary for JUNIOR STRENGTH MOTRIN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,966
DailyMed Link:	JUNIOR STRENGTH MOTRIN at DailyMed

US Patents and Regulatory Information for JUNIOR STRENGTH MOTRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	JUNIOR STRENGTH MOTRIN	ibuprofen	TABLET, CHEWABLE;ORAL	020601-003	Nov 15, 1996		DISCN	Yes	No
Kenvue Brands	JUNIOR STRENGTH MOTRIN	ibuprofen	TABLET;ORAL	020602-001	Jun 10, 1996		OTC	No	No

Expired US Patents for JUNIOR STRENGTH MOTRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kenvue Brands	JUNIOR STRENGTH MOTRIN	ibuprofen	TABLET, CHEWABLE;ORAL	020601-003	Nov 15, 1996	5,215,755*PED

EU/EMA Drug Approvals for JUNIOR STRENGTH MOTRIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Recordati Rare Diseases	Pedea	ibuprofen	EMEA/H/C/000549Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.	Authorised	no	no	no	2004-07-28

International Patents for JUNIOR STRENGTH MOTRIN

See the table below for patents covering JUNIOR STRENGTH MOTRIN around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	94898	PROCESSO PARA A PREPARACAO DE PASTILHAS MEDICAMENTOSAS DE MASCAR ROTOGRANULADAS E COBERTAS POR REVESTIMENTO PARA MASCARAR O SABOR
New Zealand	234587	A CHEWABLE PHARMACEUTICAL TABLET OF COMPRESSED COATED GRANULES
South Korea	0166064
European Patent Office	0411952	Rotogranulations et enrobages pour masquer le goût pour la préparation de comprimés pharmaceutiques à mâcher. (Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets.)
Canada	2022640	ROTOGRANULATIONS ET ENROBAGE MASQUANT LE GOUT POUR LA PREPARATION DE COMPRIMES PHARMACEUTIQUES MASTIQUABLES (ROTOGRANULATIONS AND TASTE MASKING COATINGS FOR PREPARATION OF CHEWABLE PHARMACEUTICAL TABLETS)

Supplementary Protection Certificates for JUNIOR STRENGTH MOTRIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1781277	PA2024501	Lithuania		PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726

Market Dynamics and Financial Trajectory for JUNIOR STRENGTH MOTRIN

Last updated: August 1, 2025

---

Introduction

Junior Strength Motrin, a popular over-the-counter (OTC) analgesic and antipyretic medication, primarily containing ibuprofen, commands a significant position within the pediatric pain relief segment. Its strategic placement in the pain management market, combined with evolving consumer behaviors and regulatory landscapes, influences its market dynamics and financial trajectory. This comprehensive analysis explores the factors shaping its current standing, growth potential, and future outlook.

---

Market Overview

The global OTC analgesics market value was estimated at approximately USD 13 billion in 2022, with pediatric formulations, including Junior Strength Motrin, accounting for a substantial share (Grand View Research, 2022). The continuous demand for effective, accessible pediatric pain relief options sustains robust sales figures, driven by increasing awareness among caregivers and healthcare providers about OTC options for minor illnesses.

Within this segment, the ibuprofen-based OTC products—including Junior Strength Motrin—benefit from a well-established efficacy profile, safety record, and consumer trust. The brand’s global presence spans North America, Europe, and parts of Asia-Pacific, with North America representing the largest market due to high OTC drug utilization and favorable regulatory support.

---

Market Dynamics

1. Consumer Preference and Brand Loyalty
Consumption patterns for pediatric OTC medications favor trusted brands with consistent efficacy profiles. Junior Strength Motrin holds a competitive advantage owing to its long-standing reputation, ease of dosing, and pediatric approvals.

2. Regulatory Environment
Regulatory agencies such as the FDA (Food and Drug Administration) in the US impose safety standards that influence formulation modifications and marketing. Recent updates focus on package labeling and safety warnings related to dosing accuracy and potential adverse effects, which can impact product perception and sales.

3. Innovation and Formulation Trends
The market witnesses ongoing product innovation, including liquid formulations with improved flavorings and dosing devices, facilitating parental acceptance and adherence. Any formulation enhancements that improve safety and efficacy can bolster market share.

4. Competitive Landscape
Key competitors include brands like Advil, Tylenol (acetaminophen-based formulations), and store-branded generics. Price competition, marketing strategies, and distribution expansion tactics continuously reshape market share dynamics.

5. Demographics and Healthcare Trends
The rising global birth rates, increased pediatric healthcare access, and proactive parental health management fuel demand. Additionally, COVID-19 underscored the importance of OTC medications for symptom management at home, benefiting brands like Junior Strength Motrin.

6. Supply Chain Considerations
Global supply chain resilience impacts availability. Raw material sourcing, manufacturing capacities, and distribution logistics directly influence sales volume and financial performance.

---

Financial Trajectory

1. Revenue Trends
Historical data indicate steady revenue growth driven by consistent demand, with an annual CAGR of approximately 3-5% pre-pandemic. The pandemic temporarily disrupted supply chains but subsequently accelerated OTC self-care trends, contributing to a rebound.

2. Cost Structure & Margins
Manufacturing costs remain stable with bulk raw material procurement. Marketing efforts focusing on pediatric health education perpetuate consumer loyalty, supporting healthy gross margins. However, increased regulatory expenditures, especially safety warnings and packaging investments, marginally pressure margins.

3. Pricing Strategies
Brand positioning varies from premium pricing to competitive discounts. Product bundling and pediatric wellness campaigns increasingly influence purchase decisions, underpinning revenue growth.

4. Market Penetration and Expansion
Expansion into emerging markets presents lucrative opportunities. Local regulatory approval processes, cultural acceptance, and economic factors shape the success of such initiatives. A strategic move into markets like India and Southeast Asia, where pediatric OTC medication adoption is growing, could amplify revenue streams.

5. Future Growth Drivers

• Product Innovation: Development of formulations with added benefits, such as combination products or natural ingredient-infused variants.
• Digital Engagement: Leveraging digital platforms for parental education and online sales.
• Regulatory Approvals: Enhanced safety labeling and pediatric indications potentially increase consumer confidence and sales.
• E-commerce Penetration: Increasing online purchase channels broadens access, especially in pandemic-affected regions.

---

Market Challenges

• Regulatory Stringency: Stringent safety regulations and label warnings could impact sales or require reformulation.
• Pricing Pressure: Competition intensifies price-based discounting, affecting profit margins.
• Generic Competition: Entry of store brands and generics erodes market share and compresses margins.
• Consumer Awareness: Misinformation regarding pain relievers could hamper brand trust.

---

Future Outlook

The financial trajectory for Junior Strength Motrin appears cautiously optimistic. In developed markets, stability persists, with growth driven by brand loyalty, innovation, and educational marketing. Emerging markets offer high growth potential, necessitating strategic adaptations to local regulatory and cultural contexts.

Forecasts project a compound annual growth rate of approximately 3-4% over the next five years, contingent on regulatory developments, competitive behavior, and consumer preferences. Companies investing in formulation innovation, digital marketing, and supply chain resilience are positioned for enhanced financial performance.

---

Key Takeaways

• The pediatric OTC analgesic segment, with Junior Strength Motrin as a key brand, remains resilient amid competitive and regulatory pressures.
• Consumer trust, product innovation, and market expansion in emerging economies underpin growth prospects.
• Regulatory and safety concerns necessitate ongoing investment in compliance and consumer education.
• E-commerce and digital engagement will be critical channels for sustained revenue growth.
• Strategic partnerships and targeted marketing can mitigate generic competition and strengthen brand positioning.

---

FAQs

1. What factors are driving the growth of Junior Strength Motrin globally?
Global growth is driven by rising pediatric healthcare awareness, consumer preference for trusted OTC brands, innovation in formulations, and expanding access in emerging markets.

2. How do regulatory changes impact Junior Strength Motrin’s market performance?
Regulatory updates, especially safety labels and dosing instructions, influence consumer perception and compliance costs, potentially affecting sales but also reinforcing safety standards.

3. What competitive strategies are companies employing in the pediatric OTC analgesic market?
Companies focus on product innovation, aggressive marketing, digital engagement, pricing strategies, and expanding distribution—particularly online—to maintain competitiveness.

4. What role does e-commerce play in the future trajectory of Junior Strength Motrin?
E-commerce channels facilitate broader access, especially during pandemic contexts, and allow targeted marketing, ultimately supporting higher sales volumes and revenue growth.

5. What are the key risks facing Junior Strength Motrin’s financial outlook?
Risks include regulatory tightening, intense price competition, generic erosion, supply chain disruptions, and misinformation affecting consumer trust.

---

Sources

[1] Grand View Research, “Over The Counter (OTC) Analgesics Market Size, Share & Trends Analysis Report,” 2022.
[2] U.S. Food & Drug Administration, “Over-the-Counter (OTC) Drug Review — Safety, Labeling, and Efficacy,” 2023.
[3] MarketWatch, “Pediatric OTC Medications Market Outlook,” 2022.